UCB Group and Immunomedics, Inc. Release: Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint

Published: Nov 08, 2011

BRUSSELS, Belgium, and CHICAGO, Nov. 8, 2011 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels:UCB) and U.S. based partner Immunomedics Inc. (Nasdaq:IMMU) today announced data, at the 75th Annual Scientific Meeting of the American College of Rheumatology (ACR) in Chicago, that supported the BILAG-based Combined Lupus Assessment (BICLA) as a clinically meaningful composite measure of systemic lupus erythematosus (SLE) disease activity.4

Back to news